


Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients

Methods



The rate of anti-SARS-CoV-2 IgG seropositivity after the second SARS-CoV-2 mRNA vaccination

Outcomes

Hamaya T. et al

Anti-SARS-CoV-2 S IgG

antibody titer ≥ 15 U/mL

Controls

KT recipients

98% vs. 22%

ABO 26% vs. ABO 8.3%
compatible incompatible

Factors associated with impaired humoral response

1. Age >53 years
2. KT vintage <7 years
3. Rituximab use
4. Mycophenolate mofetil use

Conclusion: Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients.

The Supplemental file